Compare FULC & HRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FULC | HRZN |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.4M | 322.2M |
| IPO Year | 2019 | 2010 |
| Metric | FULC | HRZN |
|---|---|---|
| Price | $3.67 | $4.36 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 6 |
| Target Price | $3.67 | ★ $5.08 |
| AVG Volume (30 Days) | ★ 1.4M | 351.7K |
| Earning Date | 10-28-2026 | 10-27-2026 |
| Dividend Yield | N/A | ★ 15.69% |
| EPS Growth | N/A | ★ 62.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.55 |
| Revenue Next Year | N/A | $14.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.83 | $3.80 |
| 52 Week High | $15.74 | $6.85 |
| Indicator | FULC | HRZN |
|---|---|---|
| Relative Strength Index (RSI) | 39.62 | 35.35 |
| Support Level | $3.62 | $4.07 |
| Resistance Level | $3.91 | $4.36 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 11.11 | 4.29 |
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.